DGAP-News: STRATEC Biomedical AG / Key word(s): Quarter Results/Interim Report STRATEC reports nine-month results 24.10.2012 / 07:37 --------------------------------------------------------------------- STRATEC reports nine-month results - Sales of EUR 87.6 million in 9M/2012 (+9.3%; 9M/2011: EUR 80.2 million) - EBIT margin of 15.3% in 9M/2012 (9M/2011: 18.8%) - Consolidated net income of EUR 10.9 million in 9M/2012 (+10.4%; 9M/2011: EUR 9.8 million) - Earnings per share of EUR 0.93 in 9M/2012 (+9.4%; 9M/2011: EUR 0.85) - 2012 forecast specified: Sales: EUR 120 million to EUR 125 million / EBIT margin:14% to 16% Birkenfeld, October 24, 2012 STRATEC Biomedical AG, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, TecDAX)today announced its results for the period from January 1, 2012 to September 30, 2012 upon the publication of its Interim Report as of September 30, 2012. <pre> Key figures (EUR 000s) 01.01.- 01.01.- Change 09.30.2012** 09.30.2011* Sales 87,584 80,155 +9.3% Overall performance 92,379 85,871 +7.6% EBITDA 16,333 17,636 -7.4% EBIT 13,357 15,065 -11.3% EBIT margin (%) 15.3 18.8 - Consolidated net income 10,865 9,840 +10.4% Earnings per share (EUR) 0.93 0.85 +9.4% </pre> * 2011: The figures are presented in the table on an unadjusted basis. Adjusted for a one-off item of EUR 1.6 million resulting from a routine tax audit for the financial years 2005 to 2008, consolidated net income for the first nine-months of 2011 would amount to EUR 11.4 million and earnings per share would amount to EUR 0.99. ** 2012: The figures are presented in the table on an unadjusted basis. Adjusted for a one-off item of EUR 3.3 million incurred in the first quarter of 2012 due to the income-neutral reclassification of unfinished services and prepayments received due to the impairment of a development project, sales for the first nine months of 2012 would amount to EUR 84.3 million and the EBIT margin would amount to 15.8%. Financial performance The third quarter of 2012 was characterized by a marked disparity between highly positive trends in development work and promising advances in the field of business development (especially new projects) on the one hand and an unexpectedly poor performance in sales with maintenance and spare parts on the other. Among other factors, the dip in these sales was chiefly attributable to lower capacity utilization rates for systems already placed on the market at end customers (laboratories, blood banks etc.). In recent months, most of STRATEC's partners have placed consistently high numbers of new systems with end customers, in some cases accepting that this would result in lower levels of system capacity utilization. This is because they expect test volumes to recover, a development which would lead capacity utilization levels to rise once again and thus benefit STRATEC's partners in future. In the short term, however, our partners are accepting lower utilization rates to the extent that these enable customer relationships to be upheld. This has resulted in longer system servicing intervals and lower servicing part consumption rates. System sales revenues have continued to develop positively at high levels. Sales with replacement and maintenance parts, by contrast, have declined both in nominal terms and as a percentage of total sales, thus virtually neutralizing the system sales growth. Nine-month sales grew by 9.3% to EUR 87.6 million. Adjusted for a one-off income-neutral reclassification of EUR 3.3 million in the first quarter due to the write-down of a development project, sales growth amounted to 5.2%. Compared with the same period in the previous year, sales for the third quarter of 2012 fell by 7.6% from EUR 31.8 million to EUR 29.3 million. The EBIT margin for the first nine months amounted to 15.3% (adjusted 15.8%), compared to 18.8% in the same period in the previous year. This reduction in the company's profitability was attributable to the following factors: a weaker than expected share of sales generated with high-margin maintenance and spare parts and a lower overall gross margin for systems newly launched onto the market and whose production and supply chain process optimization measures have not yet been completed. Moreover, the difficulties in planning market entry phases in our industry, for example due to delays in the approval of new systems by our customers, have arisen with unusual frequency in the current year. As a result, the corresponding sales will be postponed to the coming year. Furthermore, the company is continuing its investment programs aimed at stepping up its development activities. These have resulted in negative earnings contributions from our main subsidiaries. At EUR 10.9 million, consolidated net income for the first nine months of 2012 was 10.4% up on the previous year's figure of EUR 9.8 million, resulting in earnings per share of EUR 0.93 (previous year: EUR 0.85). If the previous year's figure is adjusted to exclude a one-off tax back payment of EUR 1.6 million for the financial years 2005 through 2008, the consolidated net income posted for 2012 fell 5.0% short of the previous year's figure. Project development Further new market launches are expected in the current and subsequent years. Specifically, two additional market launches by our partners are foreseen in the fourth quarter of the current year. In liaison with our partners, it is planned to release further details about the new systems once their market launches have been implemented. Preparatory development work has already begun on further new projects currently under negotiation. STRATEC is optimistic that it will be awarded follow-up contracts for these projects. These would contribute notably to STRATEC's sales performance from the 2015 and 2016 financial years. Further details of these contracts will be published following agreement. Significant progress is expected to be made in the next two quarters with optimizing supply and production for analyzer systems recently launched onto the market. This will enable an enhanced gross margin to be generated with these systems. Other developments During the course of the 2012 financial year, STRATEC plans to convert its accounting from the total cost method to the cost of sales method, which is more widespread internationally and should thus help in comparing the company's performance with that of other players. In this context, parallel application of the two methods has been made once again in the statement of comprehensive income in this interim report. This should facilitate comparison of the two methods. The final conversion will then be implemented from the start of the next financial year, as of January 1, 2013. Development in staff totals Including temporary employees, the STRATEC Group had a total of 524 employees as of September 30, 2012 (September 30, 2011: 484). Outlook The company previously expected its sales performance to accelerate in the second half of 2012, with this chiefly being driven by two further market launches. Given that these market launches will take place later than expected, this acceleration has not arisen to the extent previously anticipated and will only give rise to notable sales growth from the first half of 2013 onwards. As a result, STRATEC expects to generate sales in a range of EUR 120 million to EUR 125 million in the 2012 financial year (previous guidance: EUR 125 million to EUR 139 million). Due to further market launches and based on our customers' forecasts, we expect to see a positive sales performance in 2013. The company forecast is planned to be updated around the time of publication of the 2012 Annual Report in April 2013. For 2012 to 2014, we are upholding our forecast of expected average sales growth of 14% to 16% based on the 2011 sales figure (EUR 116.6m). Accordingly, sales of EUR 151 million to EUR 157 million could be expected in 2013. The achievement or exceeding of this range is dependent on the performance of the systems newly launched onto the market at the end of 2012 and on follow-up approvals, as well as on the further progress made with development projects and associated reclassifications from milestone payments to sales. In terms of our costs, margins will continue to be held back by investments in new development programs. In the medium term, however, the margin is expected to recover due to benefits of scale arising in particular from the higher expected share of sales generated with maintenance and spare parts. Further details can be found in our Interim Report as of September 30, 2012 published at www.stratec.com > Investor Relations > IR News > Financial Reports. About STRATEC STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange. Further information can be obtained from: STRATEC Biomedical AG André Loy, Investor Relations Gewerbestr. 37, 75217 Birkenfeld Germany Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 ir@stratec.com www.stratec.com End of Corporate News --------------------------------------------------------------------- 24.10.2012 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: STRATEC Biomedical AG Gewerbestr. 37 75217 Birkenfeld Germany Phone: +49 (0)7082 7916 0 Fax: +49 (0)7082 7916 999 E-mail: info@stratec.com Internet: www.stratec.com ISIN: DE0007289001 WKN: 728900 Indices: TecDAX Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 189911 24.10.2012
DGAP-News: STRATEC reports nine-month results
| Source: EQS Group AG